Skip to main content

Table 1 GCS score compared with the number of deaths in each treatment group, as well as the total deaths for each GCS group.

From: Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury

GCS

Placebo

Low

Medium

High

Total Deaths

Deaths/patient treated by cohort

3

3

0

0

3

6

16%

4

0

0

0

1

1

 

5

1

1

1

0

3

 

6

2

7

3

0

12

32%

7

0

1

3

2

6

 

8

3

0

1

0

4

 

9

2

0

2

2

6

15%

10

0

0

1

1

2

 

11

0

0

0

0

2

 

12

0

1

1

1

3

 

Total Deaths

11

10

12

12

45

 
  1. The three cohorts (GCS 3-5, GCS 6-8, and GCS 9-12) are the same cohorts used in the BRAIN TRIAL to achieve balance among treatment groups.